Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([e-mail]), or visit us at https://www.ksfcounsel.com/cases/nyse-ogn/ to learn more.

On October 27, 2025, the Company disclosed the resignation of CEO Kevin Ali following results from an internal investigation where an audit committee discovered that select U.S. wholesalers were asked to purchase additional Nexplanon at the end of several quarters between 2022 and 2025. The results of the investigation indicated that these sales represented less than 1% of the company’s consolidated revenue for 2022, and 2024, yet the metrics enabled the Company to meet guidance, and certain external revenue expectations.

The investigation concerns whether Organon and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20251114577183/en/

The Organon & Company Stock at the time of publication of the news with a fall of -1,18 % to 7,53EUR on NYSE stock exchange (14. November 2025, 23:05 Uhr).